Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day

Executive Summary

Immunovant is Roivant's 10th drug development-focused firm, progressing RVT-1401, an antibody targeting neonatal Fc receptor (FcRn) in immunoglobulin-mediated autoimmune diseases. Roivant showcased the budding pipeline of its growing family of companies, which now has 12 "vants."

Advertisement

Related Content

Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune
Roivant's New Respiratory-Focused Vant Adds Chronic Cough Candidate To The Portfolio
Axovant Hopes Gene Silence Is Golden With Benitec Pact
Roivant Cuts Jobs, Reallocates Staff As It Prepares To Put New Stars In The Spotlight
Oxford BioMedica CEO To Hire More People, Expects More Deals Following Gene Therapy Pact With Axovant
Argenx Nears Phase III In Myasthenia Gravis
Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure
Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies
What's Next For Roivant? It's Not More Publicly Traded "Vants"
Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123390

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel